Q1 Earnings Forecast for APLS Issued By William Blair

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Equities researchers at William Blair issued their Q1 2025 earnings estimates for shares of Apellis Pharmaceuticals in a report issued on Monday, October 28th. William Blair analyst L. Hanbury-Brown anticipates that the company will post earnings per share of ($0.09) for the quarter. William Blair has a “Outperform” rating on the stock. The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.37) per share. William Blair also issued estimates for Apellis Pharmaceuticals’ Q2 2025 earnings at $0.06 EPS and Q3 2025 earnings at $0.13 EPS.

A number of other equities analysts also recently issued reports on the stock. Robert W. Baird cut their price objective on shares of Apellis Pharmaceuticals from $96.00 to $92.00 and set an “outperform” rating on the stock in a report on Monday, September 23rd. Jefferies Financial Group reiterated a “buy” rating and set a $80.00 price target on shares of Apellis Pharmaceuticals in a research report on Wednesday, July 31st. Wells Fargo & Company lowered their target price on shares of Apellis Pharmaceuticals from $47.00 to $43.00 and set an “equal weight” rating on the stock in a research note on Tuesday, September 24th. Needham & Company LLC reiterated a “buy” rating and set a $85.00 price target on shares of Apellis Pharmaceuticals in a research report on Friday, September 20th. Finally, Royal Bank of Canada initiated coverage on shares of Apellis Pharmaceuticals in a report on Friday, October 25th. They issued a “sector perform” rating and a $25.00 target price on the stock. Five equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Apellis Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $65.41.

Apellis Pharmaceuticals Price Performance

APLS opened at $27.71 on Thursday. The company has a debt-to-equity ratio of 1.73, a current ratio of 5.08 and a quick ratio of 4.18. The company has a market capitalization of $3.36 billion, a price-to-earnings ratio of -8.01 and a beta of 0.87. The firm’s fifty day moving average price is $32.76 and its two-hundred day moving average price is $38.01. Apellis Pharmaceuticals has a 1 year low of $26.28 and a 1 year high of $73.80.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings data on Thursday, August 1st. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.03. The firm had revenue of $199.70 million for the quarter, compared to the consensus estimate of $190.89 million. Apellis Pharmaceuticals had a negative net margin of 52.99% and a negative return on equity of 138.32%. The business’s revenue for the quarter was up 110.2% compared to the same quarter last year. During the same period in the previous year, the firm earned ($1.02) EPS.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Several large investors have recently modified their holdings of APLS. Assenagon Asset Management S.A. increased its holdings in Apellis Pharmaceuticals by 191.9% in the 3rd quarter. Assenagon Asset Management S.A. now owns 2,144,415 shares of the company’s stock worth $61,845,000 after buying an additional 1,409,707 shares in the last quarter. Fiera Capital Corp grew its stake in shares of Apellis Pharmaceuticals by 47.7% during the 2nd quarter. Fiera Capital Corp now owns 1,401,190 shares of the company’s stock valued at $53,750,000 after purchasing an additional 452,753 shares during the period. Iron Triangle Partners LP bought a new stake in shares of Apellis Pharmaceuticals during the 1st quarter valued at about $32,329,000. Bank of New York Mellon Corp grew its stake in shares of Apellis Pharmaceuticals by 6.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 345,195 shares of the company’s stock valued at $13,242,000 after purchasing an additional 22,273 shares during the period. Finally, Altitude Crest Partners Inc. grew its stake in shares of Apellis Pharmaceuticals by 88.7% during the 1st quarter. Altitude Crest Partners Inc. now owns 287,277 shares of the company’s stock valued at $16,886,000 after purchasing an additional 135,077 shares during the period. Hedge funds and other institutional investors own 96.29% of the company’s stock.

Insider Buying and Selling at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, Director A. Sinclair Dunlop sold 37,000 shares of the firm’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of $36.23, for a total transaction of $1,340,510.00. Following the completion of the transaction, the director now owns 100,000 shares of the company’s stock, valued at approximately $3,623,000. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 6.80% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).